Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Becker

Showing results (191-200 of 194) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 194 results.
ESMO Open|May 25, 2024
Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upI Lugowska, J C Becker, P A Ascierto, et al.
The British Journal of Dermatology|June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2006
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGD Schadendorf, S Ugurel, B Schuler-Thurner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
Pageof 20

Showing results (191-200 of 194) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 194 results.
ESMO Open|May 25, 2024
Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-upI Lugowska, J C Becker, P A Ascierto, et al.
The British Journal of Dermatology|June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2006
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGD Schadendorf, S Ugurel, B Schuler-Thurner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2014
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survivalS Ugurel, C Loquai, K Kähler, et al.
Pageof 20